PEPG - NASDAQ
PepGen Inc.
$1.46
+3.0%PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotPepGen Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
PepGen Inc. Cash Flow Statement
PEPG • NASDAQ
| PepGen Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-89.7M | -90M | -78.6M | -69.1M | -27.3M | -1.9M | -1.3M | |
5.1M | 5.3M | 850K | 493K | 178K | 110K | 106K | |
10.6M | 11.5M | 7M | 4.8M | 1.5M | 119K | 0.0 | |
-1.5M | -3.9M | -220K | 76K | 196K | 0.0 | 59K | |
(0.0) | (71K) | (2.7M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-6.2M | -5.2M | 2M | 4.5M | 2.8M | 8K | 296K | |
-81.6M | -82.4M | -69M | -59.3M | -22.6M | -1.7M | -885K | |
INVESTING ACTIVITIES | |||||||
-264K | -497K | -2.6M | -3.8M | -500K | -8K | -29K | |
-94M | -145.2M | -29.4M | (0.0) | (0.0) | (0.0) | (0.0) | |
79M | 108M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-15.2M | -37.7M | -32M | -3.8M | -500K | -8K | -29K | |
FINANCING ACTIVITIES | |||||||
108M | 86.8M | 0.0 | 114.3M | 0.0 | 0.0 | 2.8M | |
0.0 | 2M | -189K | -2.1M | -1.4M | -3K | 0.0 | |
108M | 88.7M | -189K | 112.2M | 147.7M | 8M | 2.8M | |
CASH FLOW SUMMARY | |||||||
-16K | -62K | 286K | -316K | 33K | -5K | 62.0 | |
11.1M | -31.4M | -100.9M | 48.9M | 124.6M | 6.3M | 1.9M | |
51M | 82.3M | 183.2M | 134.4M | 9.8M | 3.5M | 1.6M | |
62.1M | 51M | 82.3M | 183.2M | 134.4M | 9.8M | 3.5M | |
-81.9M | -82.9M | -71.6M | -63M | -23.1M | -1.7M | -914K |
SEC Filings
PEPG - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
S-3 S-3 N/A | May 18, 2026 | May 18, 2026 | ||
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 |
Related Guides
Continue your PEPG research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.